LONDON, Nov. 28, 2017 /PRNewswire/ — Will oral therapies transform the treatment of ulcerative colitis?
With Pfizer’s Xeljanz (tofacitinib) pending approval in the US, new oral therapies are set to transform the ulcerative colitis (UC) treatment landscape. While Pfizer’s JAK inhibitor clearly has a head-start, other companies have more selective JAK1-inhibitors in late-stage development, including AbbVie’s upadacitinib and Galapagos/Gilead Sciences’ filgotinib.
Download the full report: https://www.reportbuyer.com/product/5214603
Celgene has taken a different approach with its oral molecule, ozanimod. Do KOLs believe they’ll all be successful? Other late-stage programmes, including Roche’s subcutaneous integrin inhibitor, etrolizumab, and Johnson & Johnson’s Stelara (ustekinumab), will also add complexity and choice to the treatment algorithm. How will these products fare in an increasingly competitive environment, where anti-TNF biosimilars look set to dominate? KOLs provide candid insights on these and other new therapies, their likely use, and how they’ll affect current mainstays such as anti-TNFs and Takeda’s Entyvio (vedolizumab), in KOL Insight: Ulcerative Colitis.
Twelve North American and European KOLs provide their insight on 5 marketed/registered products and 9 late-stage pipeline programmes.
Take a tour of the report now
The table of contents >
The key business questions answered >
The key KOL quotes >
See the therapies covered >
Find out who the 6 EU & 6 US KOLs are >
Review an extract from the report – 1 drug profile >
• An addition to mild-to-moderate disease? Mild-to-moderate UC is currently treated with cheap, generic 5-ASA, but can Lipid Therapeutics’ LT-02 add clinical value? What do KOLs view as LT-02’s specific advantages?
• Optimism for biosimilar anti-TNFs continues to grow. An increasing number of KOLs are using these products. But in which patients are these agents used, and are they having an equal impact in both the US and EU markets?
• Etrolizumab set to challenge Entyvio? Roche’s etrolizumab is a subcutaneous integrin inhibitor undergoing late-stage evaluation. Do KOLs believe this agent will be a threat to Takeda’s Entyvio (vedolizumab)?
• Stelara (ustekinumab) will add more choice to the treatment algorithm. KOLs agree that Johnson & Johnson’s Stelara has shown great efficacy in Crohn’s disease. But can this translate to UC, and what are Stelara’s specific advantages?
• KOLs excited by the arrival of oral therapies. With Pfizer’s Xeljanz (tofacitinib) pending approval for UC in the US, several other JAK inhibitors in late-stage development and Celgene’s ozanimod in Phase III trials, KOLs are understandably excited. How are these agents expected to be used?
• Will enema formulations for moderate-to-severe disease